Clinical Trial Detail

NCT ID NCT02880371
Title A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Array BioPharma


stomach cancer

colorectal cancer

triple-receptor negative breast cancer

lung non-small cell carcinoma

urinary bladder cancer

head and neck squamous cell carcinoma

ovarian cancer

pancreatic ductal adenocarcinoma


ARRY-382 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.